natgillin/translations-raw huggingface dataset:
Kinzalmono не се препоръчва в ранна бременност и не трябва да се приема, ако сте бременна след третия месец, тъй като може сериозно да увреди Вашето дете, ако се използва след третия месец от бременността.
Kinzalmono is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Kinzalmono не се препоръчва на майки, които кърмят и Вашият лекар може да Ви назначи друго лечение, ако искате да кърмите, особено ако Вашето дете е новородено или е родено преждевременно.
Kinzalmono is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Kinzalmono се предлага в блистери, съдържащи 14, 28, 56 или 98 таблетки.
Kinzalmono is available in blister packs containing 14, 28, 56, or 98 tablets.
KIOVIG 100 mg/ml инфузионен разтвор Human normal immunoglobulin Интравенозно приложение
KIOVIG 100 mg/ml solution for infusion Human Normal Immunoglobulin Intravenous use.
Kiovig е лекарство, което съдържа активното вещество човешки нормален имуноглобулин (human normal immunoglobulin).
Kiovig is a medicine that contains the active substance human normal immunoglobulin.
Kiovig може да се разрежда преди прилагане.
Kiovig can be diluted before being given.
Kiovig не трябва да се прилага при хора, които са свръхчувствителни (алергични) към нормалния човешки имуноглобулин или към някоя от останалите съставки, или при пациенти, които са алергични към други видове човешки имуноглобулин, особено когато имат антитела срещу имуноглобулин A (IgA).
Kiovig must not be used in people who are hypersensitive (allergic) to human normal immunoglobulin or any of the other ingredients, or in patients who are allergic to other types of human immunoglobulin, especially where they have antibodies against immunoglobulin A (IgA).
Kiovig се използва при възрастни и деца, които се нуждаят от повече антитела в кръвта, за да се подпомогне борбата с инфекции и други заболявания.
Kiovig is used in adults and children who need more antibodies in their blood to help fight infections and other diseases.
Kiovig се използва също за лечение на определени разстройства на имунната система:
Kiovig is also used to treat certain immune system disorders:
KIOVIG се приготвя от човешка плазма (течната съставка на кръвта).
KIOVIG is made from human plasma (the liquid part of blood).
KIOVIG се прилага за
KIOVIG is used for
KIOVIG се прилага само интравенозно.
KIOVIG must only be administered intravenously.
Kiovig се прилага чрез вливане във вената от лекар или медицинска сестра.
Kiovig is given as an infusion into a vein by a doctor or nurse.
KIOVIG се произвежда от човешка плазма.
KIOVIG is made from human plasma.
KIOVIG трябва да се въвежда венозно при начална скорост 0,5 ml/kg ТТ на час за 30 минути.
KIOVIG should be infused intravenously at an initial rate of 0.5 ml/kg bodyweight/hour for 30 minutes.
Kiovig човешки нормален имуноглобулин
Kiovig human normal immunoglobulin
Kiryat Malachi 83104 Израел
Kiryat Malachi 83104 Israel
Kiryat Ono 5510801 Израел
Kiryat Ono 5510801 Israel
kisika/hipoksemija), ki nastane ob nenadni prekinitvi zdravljenja; glavobol, omotica, suho grlo ali zasoplost po nenamerni izpostavljenosti dušikovemu oksidu v zraku okolja (npr. pri puščanju opreme ali jeklenke).
Headache, dizziness, dry throat or shortness of breath following accidental ambient air exposure to nitric oxide (e.g. leakage from equipment or cylinder).
kisika/hipoksemija), ki nastane ob nenadni prekinitvi zdravljenja; glavobol, omotica, suho grlo ali zasoplost po nenamerni izpostavljenosti dušikovemu oksidu v zraku okolja (npr. pri puščanju opreme ali jeklenke)..
Headache, dizziness, dry throat or shortness of breath following accidental ambient air exposure to nitric oxide (e.g. leakage from equipment or cylinder).
Kisplyx 10 mg твърда капсула: жълто тяло и жълтеникаво-червено капаче, с дължина приблизително 14,3 mm, маркирана с черно мастило с „Є“ върху капачето и „LENV 10 mg“ върху тялото.
Kisplyx 10 mg hard capsule: yellow body and yellowish red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 10 mg” on the body.
Kisplyx 10 mg твърди капсули
Kisplyx 10 mg hard capsules
Kisplyx 10 mg твърди капсули ленватиниб
Kisplyx 10 mg hard capsules lenvatinib
Kisplyx 10 mg твърди капсули: всяка твърда капсула съдържа 10 mg ленватиниб (под формата на мезилат).
Kisplyx 10 mg hard capsules: - Each hard capsule contains 10 mg of lenvatinib (as mesilate).
Kisplyx 4 mg твърди капсули ленватиниб
Kisplyx 4 mg hard capsules lenvatinib
Kisplyx 4 mg твърди капсули: всяка твърда капсула съдържа 4 mg ленватиниб (под формата на мезилат).
Kisplyx 4 mg hard capsules: - Each hard capsule contains 4 mg of lenvatinib (as mesilate).
Kisplyx е лекарство против рак, което се използва за лечение на възрастни с напреднал бъбречноклетъчен карцином (вид рак на бъбреците), лекувани преди това с тип лекарство против рак, наречено „инхибитор на съдовия ендотелен растежен фактор (VEGF)“.
Kisplyx is a cancer medicine used to treat adults with advanced renal cell carcinoma (a type of kidney cancer) who have been previously treated with a type of cancer medicine called a ‘vascular endothelial growth factor (VEGF) inhibitor’.
Kivexa (абакавир /ламивудин) таблетки Носете тази карта постоянно с Вас
Kivexa (abacavir / lamivudine) tablets Carry this card with you at all times
Kivexa 600 mg/300 mg таблетки абакавир/ламивудин
Kivexa 600 mg/300 mg tablets. abacavir/lamivudine
Kivexa 600 mg/300 mg филмирани таблетки
Kivexa 600 mg/300 mg film-coated tablets
Kivexa 600 mg/300 mg филмирани таблетки абакавир/ламивудин (abacavir/lamivudine)
Kivexa 600 mg/300 mg film-coated tablets abacavir/lamivudine
Kivexa е лекарство, което съдържа две активни вещества — абакавир (abacavir) (600 mg) и ламивудин (lamivudine) (300 mg).
Kivexa is a medicine that contains two active substances, abacavir (600 mg) and lamivudine (300 mg).
Kivexa може да причини нежелани реакции, които да засегнат Вашата способност за шофиране или работа с машини.
Kivexa may cause side effects which could affect your ability to drive or use machines.
Kivexa може да се прилага със или без храна.
Kivexa can be taken with or without food.
Kivexa не трябва да се приема с други лекарствени продукти, съдържащи ламивудин (вж. точка 4.4).
Kivexa should not be taken with any other medicinal products containing lamivudine (see section 4.4).
Kivexa помага за контролиране на Вашето заболяване.
Kivexa helps to control your condition.
Kivexa се използва в комбинация с най-малко още едно антивирусно лекарство за лечение на възрастни и деца с тегло най-малко 25 kg, заразени с човешки имунoдефицитен вирус (ХИВ) — вирусът, който причинява синдром на придобита имунна недостатъчност (СПИН).
Kivexa is used in combination with at least one other antiviral medicine to treat adults and children weighing at least 25 kg who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Kivexa съдържа абакавир (което е активното вещество и в лекарствата Trizivir, Triumeq и Ziagen).
Kivexa contains abacavir (which is also an active substance in medicines such as Trizivir, Triumeq and Ziagen).
Kivexa съдържа оцветител, наречен сънсет жълто (E110), който може да причини алергични реакции при някои хора.
Kivexa contains a colouring called sunset yellow (E110), this may cause allergic reactions in some people.
Kivexa филмирани таблетки са с гравиран надпис ‘GS FC2’ от едната страна.
Kivexa film-coated tablets are engraved with ‘GS FC2’ on one side.
Kivexa, Trizivir или Triumeq), тъй като в рамките на часове може да настъпи животозастрашаващо понижаване на кръвното налягане или смърт.
Kivexa, Trizivir or Triumeq) again, as within hours you may experience a life-threatening lowering of your blood pressure or death.
Kivexa, Trizivir, Triumeq).
Kivexa, Trizivir, Triumeq)
Kivexa, Trizivir, Triumeq).
Kivexa, Trizivir, Triumeq) must never be re- initiated.
Kivexa, Ziagen, Triumeq).
Kivexa, Ziagen, Triumeq)
Kivexa, Ziagen, Triumeq).
Kivexa, Ziagen, Triumeq) must never be re- initiated.
Kjer je možno, bi moralo biti nadaljne ravnanje klinično indicirano ali priporočeno s strani nacionalnega centra za zastrupitve.
Further management should be as clinically indicated or as recommended by the national poisons centre, where available.
KJIl1Hl11.Hl1 )],AHHl1
CLINICAL PARTICULARS
Klarithromycin 500 mg dvakrát
Clarithromycin 500 mg twice daily
Klarithromycin AUC ↑94%
Clarithromycin AUC ↑94
Klarithromycin Cmax ↑50%
Clarithromycin Cmax ↑50% (↑32
Klarithromycin Cmin ↑160%
Clarithromycin Cmin ↑160
Klarithromycin může zvyšovat
Clarithromycin may increase
klarithromycinem.
clarithromycin.
klarithromycinu.
EVOTAZ.
KLASIFIKACE PRO VÝDEJ
GENERAL CLASSIFICATION FOR SUPPLY
Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa
Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa
KLIINILISED ANDMED
CLINICAL PARTICULARS
Klinicky významné interakce mezi přípravkem EVOTAZ a substráty pro CYP1A2, CYP2B6, CYP2C9 nebo CYP2C19 se nepředpokládají.
Clinically significant interactions between EVOTAZ and substrates of CYP1A2, CYP2B6, CYP2C9 or CYP2C19 are not expected.
Klinická relevance těchto zjištění je nejistá.
The clinical relevance of this finding is uncertain.
Klinická účinnost a bezpečnost
Clinical efficacy and safety
Klinická účinnosť
Clinical efficacy
Klinický význam tohoto účinku u pacientů léčených amiodaronem nebyl dosud objasněn.
The clinical relevance of this effect in patients receiving amiodarone treatment remains unknown.
Klinisk effekt mot följande patogener som är relevanta för de godkända indikationerna har inte fastställts, även om in vitro-studier tyder på att de skulle vara känsliga för ceftazidim/avibaktam när förvärvade resistensmekanismer inte förekommer.
Clinical efficacy has not been established against the following pathogens that are relevant to the approved indications although in vitro studies suggest that they would be susceptible to ceftazidime/avibactam in the absence of acquired mechanisms of resistance.
Klinisk effekt och säkerhet
Clinical efficacy and safety
Klinisk erfarenhet saknas av användning av emtricitabin hos spädbarn under 4 månader.
There is no clinical experience of the use of emtricitabine in infants less than 4 months of age.
Klinisk förbättring med Reconcile förväntas inom 1 eller 2 veckor.
Clinical improvement with Reconcile is expected within 1 or 2 weeks.
Klinisk förbättring med Reconcile förväntas inom 1 till 2 veckor.
Clinical improvement with Reconcile is expected within 1 to 2 weeks.
Kliniska data har påvisat att det inte finns någon interaktion mellan ceftazidim och avibaktam, eller mellan ceftazidim/avibaktam och metronidazol.
Clinical data have demonstrated that there is no interaction between ceftazidime and avibactam, and between ceftazidime/avibactam and metronidazole.
Kliniska effekt- och säkerhetsstudier av Zavicefta har utförts endast vid komplicerade intraabdominella infektioner och cUVI.
Clinical efficacy and safety studies of Zavicefta have been conducted in cIAI and cUTI only.
Kliniska studier har demonstrerat ett fördelaktigt svar för upp till 8 veckors behandling med fluoxetin.
Clinical studies have shown that a beneficial response has been demonstrated for up to 8 weeks treatment with fluoxetine.
Kliniska tecken, inkluderande kräkning vid första doseringen, kraftig salivavsöndring och vattnig avföring, har iakttagits när produkten överdoserats och getts i större doser än 20 mg/kg.
Clinical signs including vomiting on first administration, excess salivation and watery faeces have been observed when the product has been overdosed in excess of 20 mg/kg.
Klinična pomembnost kemične reaktivnosti dušikovega oksida v tkivih ni znana.
The clinical significance of the chemical reactivity of nitric oxide in tissue is unknown.
Klinična remisija
Clinical Remission
Klinična remisija je bila definirana kot CDAI < 150; Klinični odziv je bil definiran kot zmanjšanje CDAI za vsaj 100 točk ali pa, da je dosegel klinično remisijo.
Clinical remission is defined as CDAI score < 150; Clinical response is defined as reduction in CDAI score by at least 100 points or being in clinical remission
Klinična remisija je definirana kot CDAI < 150; Klinični odziv je definiran kot zmanjšanje CDAI za vsaj 100 točk ali pa, da je dosegel klinično remisijo.
Clinical remission is defined as CDAI score < 150; Clinical response is defined as reduction in CDAI of at least 100 points or being in clinical remission
Klinična remisija pri bolnikih:
Clinical Remission in patients:
Klinična učinkovitost
Clinical efficacy
Klinična učinkovitost in varnost
Clinical efficacy
Klinična učinkovitost in varnost pri Parkinsonovi bolezni
Clinical efficacy and safety in Parkinson’s disease
Klinična učinkovitost in varnost pri Tourettovem sindromu
Clinical efficacy and safety in Tourette Disorder
Klinični odziv
Clinical Response
Klinični odziv (100 točk), 8. teden
Clinical Response (100 point), week 8
Klinični odziv (70 točk) je bil definiran kot zmanjšanje CDAI za vsaj 70 točk.
70 point response is defined as reduction in CDAI score by at least 70 points
Klinični odziv na zdravljenje je običajno opazen po 3 – 4 dneh.
A clinical response is normally seen within 3 - 4 days.
Klinični odziv na zdravljenje je običajno opazen po 3–4 dneh.
A clinical response is normally seen within 3 - 4 days.
Klinični podatki, ki podpirajo predlagani odmerek pri mladostnikih, starih od 12 do 17 let, so omejeni.
Clinical data supporting the suggested dose in the age range 12-17 years is limited.
Klinični razvojni program je bil sestavljen iz dveh 8-tedenskih študij intravenske indukcije zdravila (UNITI-1 in UNITI-2), ki jima je sledila 44-tedenska randomizirana študija odtegnitve zdravljenja in vzdrževanja odgovora pri subkutanem odmerjanju (IM-UNITI), kar skupaj predstavlja 52 tednov zdravljenja.
The clinical development program consisted of two 8-week intravenous induction studies (UNITI-1 and UNITI-2) followed by a 44 week subcutaneous randomized withdrawal maintenance study (IM-UNITI) representing 52 weeks of therapy.
Kliničnih izkušenj z akutnim prevelikim odmerjanjem zoledronske kisline je malo.
Clinical experience with acute overdose of zoledronic acid is limited.
Kliničnih podatkov o porazdelitvi radioaktivno označenih sestavin zdravila Teysuno ni.
There are no clinical data on the distribution of radiolabeled components of Teysuno.
Klinično pomembne CTC toksičnosti, o katerih so poročali pri < 1 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala cisplatin in pemetreksed, vključujejo aritmijo in motorično nevropatijo.
Clinically relevant CTC toxicities that were reported in < 1% of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.
Klinično pomembne CTC toksičnosti, o katerih so poročali pri < 1 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo supraventrikularne aritmije.
Clinically relevant CTC toxicities that were reported in < 1% of the patients that were randomly assigned to pemetrexed include supraventricular arrhythmias.
Klinično pomembne CTC toksičnosti, o katerih so poročali pri < 1 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: alergijsko reakcijo/hipersenzitivnost, multiformni eritem, supraventrikularno aritmijo in pljučno embolijo.
Clinically relevant CTC toxicity that was reported in <1% of the patients that were randomly assigned to pemetrexed include: allergic reaction/hypersensitivity, erythema multiforme, supraventricular arrhythmia and pulmonary embolism.
Klinično pomembne CTC toksičnosti, o katerih so poročali pri > 1 % in ≤ 5 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala cisplatin in pemetreksed, vključujejo: odpoved ledvic, okužbo, pireksijo, febrilno nevtropenijo, povišane AST, ALT in GGT, koprivnico in bolečino v prsnem košu.
Clinically relevant CTC toxicities that were reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Klinično pomembne laboratorijske toksičnosti stopenj 3 in 4 so bile podobne pri integriranih rezultatih faze 2 treh študij pemetrekseda kot edine učinkovine (n = 164) in faze 3 študije pemetrekseda kot edine učinkovine, opisane zgoraj, z izjemo nevtropenije (12,8 % oziroma 5,3 %) in povišanja alaninske aminotransferaze (15,2 % oziroma 1,9 %).
Clinically relevant Grade 3 and Grade 4 laboratory toxicities were similar between integrated Phase 2 results from three single-agent pemetrexed studies (N = 164) and the Phase 3 single-agent pemetrexed study described above, with the exception of neutropenia (12.8% versus 5.3%, respectively) and alanine aminotransferase elevation (15.2% versus 1.9%, respectively).
Klinično pomembne toksičnosti glede na spol so bile podobne v celotni populaciji pri bolnikih, ki so prejemali pemetreksed skupaj s cisplatinom.
Clinically relevant toxicities with respect to gender were similar to the overall population in patients receiving pemetrexed plus cisplatin.
Klinično pomembne toksičnosti, o katerih so poročali pri < 1 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: povišanje GGT, bolečino v prsnem košu, aritmijo in motorično nevropatijo.
Clinically relevant toxicity that was reported in < 1% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.
Klinično pomembne toksičnosti, o katerih so poročali pri ≥ 1 % in ≤ 5 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: povišanje AST, povišanje ALT, okužbo, febrilno nevtropenijo, odpoved ledvic, pireksijo, dehidracijo, konjuktivitis in znižan očistek kreatinina.
Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Ključna sporočila in sestavni deli Navodila za zdravnike in ostalo zdravstveno osebje so:
The key messages and components included in the Healthcare Professional educational pack are defined as follows:
Ključna sporočila v Navodilih za bolnike so:
The key messages in the patient information pack are defined as follows:
Ključni elementi, ki jih je treba zajeti pri usposabljanju zdravstvenega osebja, so opisani v nadaljevanju.
The key elements that need to be covered in training hospital personnel are as follows.
Ključni izsledki o učinkovitosti so prikazani v preglednici 6 spodaj.
The key efficacy results are shown in Table 6 below.
Kloosterstraat 6
B.V. Kloosterstraat 6
Klopidogrel a hlavní (neaktivní) cirkulující metabolit se in vitro reverzibilně vážou na plazmatické proteiny (z 98 % resp.z 94 %).
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively).
Klopidogrel byl testován v řadě in vitro a in vivo studií genotoxicity a nevykazoval žádnou genotoxickou aktivitu.
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity.
Klopidogrel in glavni krožeči (neaktivni) metabolit se in vitro reverzibilno vežeta na humane plazemske proteine (98 % oziroma 94 %).
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively).
Klopidogrel je indiciran pri:
Clopidogrel is indicated in:
Klopidogrel je nejprve metabolizován na intermediární metabolit 2-oxo- klopidogrel.
Clopidogrel is first metabolised to a 2-oxo-clopidogrel intermediate metabolite.
Klopidogrel je pomembno zmanjšal relativno tveganje za smrt zaradi kateregakoli vzroka za 7 % (p=0,029) in relativno tveganje za ponovni infarkt, kap ali smrt za 9 % (p=0,002), kar je predstavljalo absolutno zmanjšanje za 0,5 % oziroma 0,9 %.
Clopidogrel significantly reduced the relative risk of death from any cause by 7% (p=0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p=0.002), representing an absolute reduction of 0.5% and 0.9%, respectively.
Klopidogrel je predzdravilo in eden njegovih presnovkov zavira agregacijo trombocitov.
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation.
Klopidogrel je treba dajati kot enkratni dnevni odmerek 75 mg.
Clopidogrel should be given as a single daily dose of 75 mg.
Klopidogrel může být užíván s jídlem nebo nalačno.
Clopidogrel BMS may be taken with or without food.
Klopidogrel naj se pri otrocih ne uporablja iz razlogov, ki zadevajo učinkovitost (glejte poglavje 5.1).
Clopidogrel should not be used in children because of efficacy concerns (see section 5.1)
Klopidogrel není určen pro podávání dětem nebo mladistvým.
Taking other medicines:
Klopidogrel nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Clopidogrel has no or negligible influence on the ability to drive and use machines.
Klopidogrel se in vitro in in vivo presnovi po dveh glavnih presnovnih poteh: ena poteka z esterazami in povzroči hidrolizo v neaktiven karboksilnokislinski derivat (85 % presnovkov v obtoku), druga pa z več encimi citokroma P450.
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450.
Klopidogrel se užívá v jedné denní dávce 75 mg, spolu s jídlem nebo bez něj.
Clopidogrel should be given as a single daily dose of 75 mg with or without food.
Klopidogrel se v jetrih izdatno presnovi.
Clopidogrel is extensively metabolised by the liver.
Klopidogrel so preučevali v številnih študijah genotoksičnosti in vitro in in vivo, ki niso pokazale nobenega genotoksičnega učinka.
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity.
Klopidogrel Teva Pharma B.V. 75 mg
Clopidogrel Teva Pharma B.V. 75 mg
Klopidogrel Teva Pharma B.V. 75 mg filmsko obložene tablete
Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets
Klopidogrel Teva Pharma B.V. 75 mg filmsko obložene tablete klopidogrel peroralna uporaba
Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel oral use
Kloramfenikol är antagonistiskt in vitro med ceftazidim och andra cefalosporiner.
Chloramphenicol is antagonistic in vitro with ceftazidime and other cephalosporins.
Klorovodikova kislina (za uravnavanje pH-vrednosti) Natrijev hidroksid (za uravnavanje pH-vrednosti)
Hydrochloric acid (for pH-adjustment) Sodium hydroxide (for pH-adjustment)
Klozapin
Clozapine
Klåda
Pruritus
klåda en ökning i nivåerna av vissa typer av substanser i blodet (kallade ”kreatinin” och ”urea”).
itchiness an increase in the level of some types of substances in your blood (called “creatinine” and “urea”).
Klírens kreatinínu  30 ml/min (monoterapia), sérový kreatinín  1,5 mg/dl ( 132,6 μmol/l) alebo klírens kreatinínu  60 ml/min (kombinovaná liečba)
Creatinine clearance  30 ml/min (monotherapy), serum creatinine  1.5 mg/dl ( 132.6 μmol/l) or creatinine clearance  60 ml/min (combination therapy)
KM%
KM
Ko je enkrat v celici, se pemetreksed hitro in učinkovito pretvori z encimom folilpoliglutamatno sintetazo v poliglutamatne oblike.
Once in the cell, pemetrexed is rapidly and efficiently converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase.
Ko je jeklenka prazna, se ne sme zavreči.
When the gas cylinder is empty, do not discard.
Ko je jeklenka prazna, se ne sme zavreči.
When the gas cylinder is empty, it should not be discarded.